Your browser doesn't support javascript.
loading
Security and maximal tolerated doses of fluvastatin in pediatric cancer patients
López Aguilar, Enrique; Sepúlveda Vildósola, Ana Carolina; Rivera Márquez, Hugo; Cerecedo Diaz, Fernando; Valdez Sánchez, Martha; Villasis Keever, Miguel Angel.
Afiliação
  • López Aguilar, Enrique; s.af
  • Sepúlveda Vildósola, Ana Carolina; s.af
  • Rivera Márquez, Hugo; s.af
  • Cerecedo Diaz, Fernando; s.af
  • Valdez Sánchez, Martha; s.af
  • Villasis Keever, Miguel Angel; s.af
Arch. med. res ; Arch. med. res;30(2): 128-31, mar.-abr. 1999. ilus, tab
Article em En | LILACS | ID: lil-256636
Biblioteca responsável: MX1.1
RESUMO
Background. The role of cholesterol in neoplasic cell growth and its inhibition by drugs has recently been studied. Cholesterol biosynthesis inhibitors have been used as adjuvants in the treatment of cancer and possibly as prophylactic in carcinogenesis. objetive. The objetive of the study was to determine the maximal tolerated doses (MTD) and toxic effects of fluvastatin in pediatric cancer patients. Methods. This study was carried out in a thirid level Social Security Hospital in Mexico City. We included pediatric patients from april 1996 to May 1997. All were terminal cancer patients who did not respond to conventional therapies. Fluvastatin was give p.o. at doses of 2 mg/kg/day dor 14 days every 4 weeks in three patients. Subsequent cohorts of three patients each had increments of 2 mg/kg/day of the drug until maximal tolerated doses were found. Toxic effects of the drug were evaluated by physical exploration, laboratory assays and a questionnaire given to each patient. Results. Twelve patients were included. Diagnoses included two osteosarcomas, eight central nervous system tumors, one lung tumor, and one Ewing's sarcoma. Ten patients died within 1 to 18 months. Two are aolive 22 months after inclusion into the study, both with anaplasic astrocytoma. A total of 27 courses wer administered. The MTD was 8 mg/kg/day. Toxic effects were insomnia, nausea, vomiting, abdominal distention and myalgias. Txocicity was dose-dependent. Laboratory assays demonstrated no significant changes during treatment. Conclusions. Fluvastatin can be safely used at doses of 8 mg/kg/day in pediatric patients with cancer. This dose should be used in additional trials
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: LILACS Assunto principal: Indóis / Anticolesterolemiantes / Neoplasias Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Arch. med. res Assunto da revista: MEDICINA Ano de publicação: 1999 Tipo de documento: Article País de publicação: México
Buscar no Google
Coleções: 01-internacional Base de dados: LILACS Assunto principal: Indóis / Anticolesterolemiantes / Neoplasias Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Arch. med. res Assunto da revista: MEDICINA Ano de publicação: 1999 Tipo de documento: Article País de publicação: México